drugset / Trial / NCT00587431

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

NCT00587431

Phase 2 Completed 102 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.

Timeline

Start
2003-07
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 70 mg/m2
Subject Leuprolide Other / unclassified 22.5 mg Intramuscular
Subject Testosterone Small molecule 7.5 g Topical

Indications